Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple Finger-Prick replace blood draws for antiphospholipid patients?

NCT ID NCT07570511

Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a finger-stick device (Coaguchek) can accurately measure blood thickness in people with antiphospholipid syndrome who take blood thinners. Currently, these patients need regular blood draws from a vein, which is inconvenient. The study will compare finger-stick results to standard lab tests in 150 adults to see if the simpler method is reliable enough for everyday use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that finger-stick INR tests are reliable for people with antiphospholipid syndrome, making blood monitoring easier and more convenient.
What could go wrong
This is an early observational study with no treatment being tested. It may find that finger-stick tests are not accurate enough, so current practice may not change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with APS treated with vitamin K antagonists (VKAs) * Patients with an LA profile without aCL or anti-β2GPI (isolated LA) * Patients with an LA and aCL + anti-β2GPI profile (triple positivity) * Patients with another biological profile (other than isolated LA or triple positivity) * Control patients without aCL or anti-β2GPI treated with VKAs * Adult patients * Patients who have undergone a prior clinical examination appropriate for the research * Individuals who have received complete information on the organization of the research and have not objected to their participation and the use of their data * Patients covered by a social security scheme Exclusion Criteria: * Patients with antiphospholipid syndrome (APS) not treated with vitamin K antagonists (VKAs) * Women of childbearing age without effective contraception * Persons covered by Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code: * Pregnant, parturient, or breastfeeding women * Unemancipated minors * Adults under legal protection (guardianship, curatorship, or protective supervision)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiphospholipid syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiphospholipid syndrome Vitamine K antagonist (VKA) treatment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU de Nancy

    Vandœuvre-lès-Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.